ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2026
[The Relationship Between Interleukin-4, C-reactive Protein, Atopic Dermatitis, and the Therapeutic Effect of Dupilumab].
Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the relationship between interleukin-4 (IL-4), C-reactive protein (CRP), and the incidence, severity, and therapeutic efficacy of Dupilumab in atopic dermatitis. Methods: A total of 106 patients with atopic dermatitis treated from February 2022 to November 2023 were retrospectively selected as the study group, and 50 healthy volunteers from the same period were selected as the control group. The levels of IL-4 and CRP were measured at different stages (acute, subacute, chronic) and severities (mild, moderate, severe) in both the study and control groups. Receiver operating characteristic (ROC) curves were used to analyze the diagnostic value of IL-4 and CRP in atopic dermatitis. Spearman analysis was used to assess the relationship between the severity of atopic dermatitis and the levels of IL-4 and CRP in patients. All patients with atopic dermatitis received standardized 16-week treatment with pembrolizumab and were divided into effective and ineffective treatment groups. Changes in IL-4 and CRP levels before treatment and at 4, 8, 12, and 16 weeks of treatment were compared, and the correlation between IL-4, CRP, and treatment efficacy at each time point after treatment was analyzed. Results: The levels of IL-4 and CRP were lowest in the chronic phase, higher in the subacute phase, and highest in the acute phase ( Conclusion: IL-4 and CRP are correlated to the occurrence and development of atopic dermatitis. After treatment with Dupilumab, the levels of IL-4 and CRP in patients significantly decreased. IL-4 and CRP have diagnostic value for atopic dermatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.